Page last updated: 2024-10-24

candesartan and Cancer of Prostate

candesartan has been researched along with Cancer of Prostate in 6 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Research Excerpts

ExcerptRelevanceReference
"The effect of ARBs on prostate cancer in experimental models compared with meta-analysis data from clinical trials is conflicting."1.40Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis. ( Al-Azayzih, A; Alhusban, A; Fagan, SC; Gao, F; Goc, A; Somanath, PR, 2014)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alhusban, A1
Al-Azayzih, A1
Goc, A1
Gao, F1
Fagan, SC1
Somanath, PR1
Takahashi, S1
Uemura, H4
Seeni, A1
Tang, M1
Komiya, M1
Long, N1
Ishiguro, H3
Kubota, Y4
Shirai, T1
Ikeda, N1
Nakaigawa, N3
Ouchi, H1
Yamagishi, T1
Noguchi, K2
Hasumi, H1
Kawahara, T1
Sugiura, S1
Miyoshi, Y1
Teranishi, J1
Kosaka, T1
Miyajima, A1
Takayama, E1
Kikuchi, E1
Nakashima, J1
Ohigashi, T1
Asano, T1
Sakamoto, M1
Okita, H1
Murai, M1
Hayakawa, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487]Early Phase 142 participants (Anticipated)Interventional2024-01-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for candesartan and Cancer of Prostate

ArticleYear
[A novel molecular target therapeutics for refractory prostate cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11

    Topics: Alitretinoin; Androgens; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compoun

2002

Trials

1 trial available for candesartan and Cancer of Prostate

ArticleYear
Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.
    International journal of clinical oncology, 2005, Volume: 10, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Age

2005

Other Studies

4 other studies available for candesartan and Cancer of Prostate

ArticleYear
Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 350, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Cell Movemen

2014
Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.
    The Prostate, 2012, Oct-01, Volume: 72, Issue:14

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Biphenyl Com

2012
Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer.
    The Journal of urology, 2005, Volume: 173, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Agents, Hormonal; Benzimidazoles; Biph

2005
Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
    The Prostate, 2007, Jan-01, Volume: 67, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals;

2007